



FIMECS Presents at Virtual Symposium: Targeted Protein Degradation & PROTAC

Kanagawa, Japan, 14 Feb 2021 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kanae Gamo, Ph.D., Chief Scientific Officer of FIMECS, will make a presentation at the Virtual Symposium: Targeted Protein Degradation & PROTAC (16-17 February, 2021, Virtual Symposium). A keynote address, “Discovery of Degraders Targeting Pseudokinase IRAK-M for Cancer Immunotherapy” will be scheduled on 16 February, 2021 at 9:30am GMT (UTC+0), which focused on our IRAK-M degrader program.

For more information:

<https://www.oxfordglobal.co.uk/virtual-symposium-targeted-protein-degradation/>

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. <https://www.fimecs.com/eng/>

###

FIMECS, Inc. Media and Investor Contact:

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

TEL: +81-466-32-1169

E-mail: info@fimecs.com